Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Francisco Javier Perez is active.

Publication


Featured researches published by Francisco Javier Perez.


Medicina Clinica | 2008

Adaptación psicológica y prevalencia de trastornos mentales en pacientes con cáncer

Francisco Luis Gil Moncayo; Gemma Costa Requena; Francisco Javier Perez; Manel Salamero; Nuria Sánchez; Agustina Sirgo

BACKGROUND AND OBJECTIVE: The main objective of this study was to determine the prevalence and the predictors of mental disorders in cancer patients. PATIENTS AND METHOD: 400 ambulatory cancer patients were included in the study. All the patients with a score of 14 or higher in the Hospital Anxiety and Depression Scale (HADS) received a structured clinical interview (SCID-I. DSMIV) with the objective of determining the prevalence of mental disorders. RESULTS: 24% cancer patients had criteria for a mental disorder. The predictors of mental disorders were radiotherapy treatment, psychopharmacological treatment and pain. CONCLUSIONS: These results support the need to assess the possible anxious and depressive symptoms during cancer treatment and follow up. The predictors found can help to detect possible psychiatric cases in cancer patients.


Clinical & Translational Oncology | 2007

The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity

M. Majem; M.C. Galan; Francisco Javier Perez; M. Muñoz; S. Chicote; G. Soler; M. Navarro; M. Martínez-Villacampa; X. García del Muro; E. Dotor; B. Laquente; Josep Ramon Germà


Journal of Clinical Oncology | 2017

Phase II study of dovitinib in first-line metastatic or nonresectable primary adrenocortical carcinoma (ACC): SOGUG study 2011-03.

Jesús García-Donas; Susana Hernando Polo; Marta Guix; Miguel Angel Climent Duran; María José Méndez-Vidal; Paula Jiménez-Fonseca; Nuria Lainez; Luis Leon Mateos; Fernando Salvador Moreno; Eduardo Raul Segura Gonzalez; Ignacio Duran; Francisco Javier Perez; Juan Francisco Rodriguez-Moreno; S. Macia; Sergio Vazquez-Estevez; Jose Angel Arranz; Daniel Castellano; Cristina Rodriguez de Antona


Journal of Clinical Oncology | 2010

Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).

I. Blancas; Serafin Morales; Nieves Díaz; Agust Barnadas; M. L. Gonzálvez; S. del Barco; M. H. Lopez de Ceballos; Francisco Javier Perez; A. Llombart-Cussac


Journal of Clinical Oncology | 2018

Oncogeriatric screening in patients with colorectal cancer: Is it a good tool for making decisions about their treatment?

Gemma Soler; Juan Antonio Marín; Raquel Legido; Juana Saldaña; Mercedes Martinez Villacampa; Francisco Javier Perez; Idoia Morilla; Beatriz Pardo-Burdalo; Lucia Heras; Silvia Vazquez; Sabela Recalde; Maria Plana; Cristina Santos; Nuria Mulet; Alexandre Teule; Jose Carlos Ruffinelli; Ramon Salazar


Annals of Oncology | 2018

570PDetection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool?

Gemma Soler; J C Ruffinelli Rodriguez; Raquel Legido; M Martinez Villacampa; Francisco Javier Perez; Beatriz Pardo-Burdalo; Juan Antonio Marín; I Morilla Ruiz; L Heras Lopez; Sergio Vazquez; Sergio Recalde; M Plana Serrahima; Caroline Polli Santos; N Mulet Margalef; Alexandre Teule; R Salazar; M C Galan; Juana Saldaña


Journal of Clinical Oncology | 2017

Prospective assessment of circulating endothelial cells (CECs) as markers of activity of first-line treatment in advanced clear cell renal cell carcinoma (CCRCC): The CIRCLES study (SOGUG 2011-01).

Daniel Castellano; Emilio Esteban; Luis Leon Mateos; Aranzazu Gonzalez del Alba; María José Méndez-Vidal; Jose Angel Arranz Arija; Xavier Garcia del Muro; Laura Basterrechea; Miguel Angel Climent Duran; Francisco Javier Perez; Juan Francisco Rodriguez-Moreno; Juan Virizuela Echaburu; Susana Hernando Polo; Jesús García-Donas


Journal of Clinical Oncology | 2017

A phase II study of cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Interim analysis.

Oscar Juan Vidal; Sergio Vazquez-Estevez; Vicente Giner; Joaquin Casal Rubio; J. L. Fírvida; Francisco Aparisi; José Muñoz-Langa; Jose Garcia Sanchez; Regina Gironés; Francisco Javier Perez; Alfredo Sanchez-Hernandez


Journal of Clinical Oncology | 2017

Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma (pa): a single center serie.

Helena Verdaguer; Berta Laquente; Juli Busquets; Núria Peláez; Lluís Secanella; David Leiva; Sandra Ruiz; Inmaculada Peiro; Rafael Lopez-Urdiales; Teresa Serrano; Silvia Vazquez; Mariona Calvo; Olbia Serra; María Cambray; Nuria Baixeras; Francisco Javier Perez; Cristina Sanchez; MaCarmen Galan; Joan Fabregat


Journal of Clinical Oncology | 2017

Efficacy and safety of weekly oral vinorelbine (NVBO) as single agent in first- or second-line metastatic breast cancer (MBC).

Serafin Morales; I. Blancas; Maria Luisa Gonzalvez; Agust Barnadas; Nieves Díaz; Sonia Servitja; Sonia Del Barco; Mireia Margeli; Iciar Garcia Carbonero; Ruth Alvarez; Maria Helena Lopez de Ceballos; Francisco Javier Perez; Antonio Llombart Cussac

Collaboration


Dive into the Francisco Javier Perez's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Agust Barnadas

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Daniel Castellano

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jose Garcia Sanchez

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cristina Santos

Bellvitge University Hospital

View shared research outputs
Top Co-Authors

Avatar

David Leiva

Bellvitge University Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge